0001209191-21-032978.txt : 20210514
0001209191-21-032978.hdr.sgml : 20210514
20210514201211
ACCESSION NUMBER: 0001209191-21-032978
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20210512
FILED AS OF DATE: 20210514
DATE AS OF CHANGE: 20210514
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SLACIK CHARLES P
CENTRAL INDEX KEY: 0001204660
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-10961
FILM NUMBER: 21927013
MAIL ADDRESS:
STREET 1: 250 S. KRAEMER BLVD
CITY: BREA
STATE: CA
ZIP: 92821
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: QUIDEL CORP /DE/
CENTRAL INDEX KEY: 0000353569
STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835]
IRS NUMBER: 942573850
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9975 SUMMERS RIDGE ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
BUSINESS PHONE: 8585521100
MAIL ADDRESS:
STREET 1: 9975 SUMMERS RIDGE ROAD
CITY: SAN DIEGO
STATE: CA
ZIP: 92121
FORMER COMPANY:
FORMER CONFORMED NAME: MONOCLONAL ANTIBODIES INC /DE/
DATE OF NAME CHANGE: 19910210
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2021-05-12
0
0000353569
QUIDEL CORP /DE/
QDEL
0001204660
SLACIK CHARLES P
9975 SUMMERS RIDGE ROAD
SAN DIEGO
CA
92121
1
0
0
0
Common Stock
2021-05-12
4
M
0
1040
0.00
A
12255
D
Common Stock
2021-05-12
4
M
0
191
0.00
A
12446
D
Common Stock
2021-05-12
4
M
0
19
0.00
A
12465
D
Common Stock
2021-05-13
4
S
0
1000
113.258
D
11465
D
Common Stock
2021-05-14
4
M
0
612
0.00
A
12077
D
Common Stock
2021-05-14
4
M
0
122
0.00
A
12199
D
Restricted Stock Units
2021-05-12
4
M
0
1040
0.00
D
2021-05-12
2021-05-12
Common Stock
1040
0
D
Restricted Stock Units (Converted)
2021-05-12
4
M
0
191
0.00
D
Common Stock
191
0
D
Restricted Stock Units (Premium)
2021-05-12
4
M
0
19
0.00
D
Common Stock
19
0
D
Restricted Stock Units (Converted)
2021-05-14
4
M
0
612
0.00
D
Common Stock
612
0
D
Restricted Stock Units (Premium)
2021-05-14
4
M
0
122
0.00
D
Common Stock
122
0
D
Reflects release of restricted stock units that were previously reported on Form 4.
The weighted average sale price for these transactions was $113.258 per share, with a range of $112.62 to $120.00. Upon request, the Reporting Person hereby undertakes to provide to staff of the U.S. Securities and Exchange Commission, the Issuer, or a security holder, the full information regarding the number of shares sold at each separate price.
Restricted stock units convert into common stock on a one-for-one basis.
Shares vested and released on the transaction date pursuant to Issuer's deferred compensation plan.
Robert J. Bujarski, attorney-in-fact for Charles P. Slacik
2021-05-14